Source: CureToday articles
A patient and provider share updates on pelabresib plus Rituxan treatment, which met the MANIFEST-2 trial’s primary end point for those with myelofibrosis.
Recent Content
- (no title)
- (no title)
- Oral safusidenib begins trial as maintenance for high-grade glioma
- Outcomes of relapse after teclistamab therapy in multiple myeloma
- Canada agency backs coverage of new ovarian cancer drug
- (no title)
- Caribou’s CB-011 may be effective, safe for hard-to-treat myeloma
- Therapy wins rare pediatric disease designation for hard-to-treat glioma
- November shines a spotlight on pancreatic cancer awareness
- Cero seeking more safety, dosing data on T-cell therapy for AML